Reports Q1 revenue $, consensus $. “We have made strides in our Phase 1 SB101 trial with established clinical benefit including a 45% reduction ...

PRINCETON - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotechnology company specializing in immunotherapy treatments with a current market capitalization of $4.69 million, ...

The decision to expand the trial was made following the completion of monotherapy dose escalation for SON-1010.

Love is 'an ever-fixèd mark.' Kate Moncrief and Brendon Fox - No impediments to this marriage of true minds, true love ...

The company claims its newly upgraded model is number one in user satisfaction and speed - but its methodology is unclear.

(RTTNews) - Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage biotechnology company, announced on Tuesday the granting of a new European patent for its Fully Human Albumin Binding or ...

Sonnet has a new Thunderbolt 5 dock with four TB5 ports and an internal PCIe 4.0 NVMe SSD slot that'll work with your existing M-series Macs and ensure future compatibility with higher speeds.

Sonnet just announced its new Echo 13 Thunderbolt 5 SSD Dock, the first dock of its kind to ship. The Echo 13 includes four Thunderbolt 5 ports along with a host of other I/O. If you own a M4 Pro ...

PRINCETON, NJ, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing ...

The upgraded Claude 3.5 Sonnet, the latest and most intelligent model in the Claude model family from artificial intelligence (AI) safety and research company Anthropic, is now generally available on ...

Sonnet BioTherapeutics (SONN) announced the appointment of Stephen McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025.